As of 3:59pm ET
| +0.0035 / +0.57%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 3.50, with a high estimate of 3.50 and a low estimate of 3.50. The median estimate represents a +470.40% increase from the last price of 0.61.
The current consensus among 2 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.